Lung surfactants for neonatal respiratory distress syndrome: animal-derived or synthetic agents?
Exogenous surfactant therapy is widely used in the management of neonatal respiratory distress syndrome. Two types of surfactants are available: synthetic surfactants, and those derived from animal sources ("natural" surfactants). Both of these surfactants have been shown to be effective. In this article, we review the evidence to compare the two types of surfactants in terms of their physical properties, physiologic effects, and clinical outcomes. Natural surfactants have been shown to have advantages over synthetic surfactants in their physical properties and physiologic effects in animals, as well as in humans. A systematic review of 11 randomized clinical trials comparing natural and synthetic surfactants demonstrated that the use of natural surfactant preparations results in greater clinical benefits compared with synthetic surfactants. These benefits include a more rapid improvement in oxygenation and lung compliance after surfactant therapy, a decrease in the risk of mortality (typical relative risk 0.87; typical risk difference -0.02), and a decrease in the risk of pneumothorax (typical relative risk 0.63; typical risk difference -0.04). Although the use of natural surfactants results in a slightly increased risk of intraventricular hemorrhage (typical relative risk 1.09; typical risk difference 0.03), there is no increase in the risk of grade 3 or 4 intraventricular hemorrhage. There are theoretical but unproven risks of natural surfactants, such as transmission of infectious agents, immunogenicity and impurities in composition. The use of natural surfactants is preferred in most situations. In addition, clinicians should determine the costs of different types of surfactants in their individual practice settings and use this information in decision-making.
Department of Pediatrics, University of Vermont College of Medicine, A-121 Given Building, Burlington, VT 05401, USA.
Gautham K
GK
Suresh
Roger F
RF
Soll
D000818:Animals; D006801:Humans; D007231:Infant, Newborn; D008168:Lung / Q000737:chemistry*; D011663:Pulmonary Surfactants / Q000737:chemistry / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012127:Respiratory Distress Syndrome, Newborn / Q000188:drug therapy*; D014020:Tissue Extracts / Q000737:chemistry / Q000627:therapeutic use*
D011663:Pulmonary Surfactants; D014020:Tissue Extracts